Boston, MA 02/19/2014 (wallstreetpr) – Abbott Laboratories (NYSE:ABT) has been on the receiving end on one of its drugs, AndroGel. Apparently, five men have filed lawsuits against Abbott Laboratories (NYSE:ABT) and its recently formed subsidiary – AbbVIE Inc, for not revealing the dangers of the drug which essentially worked as a replacement for testosterone.
Abbott Laboratories (NYSE:ABT) experienced the backlash of the pliant. Stock prices slid marginally. The company, working out of IL, is engaged in the development, manufacture and discovery of health care products. The company currently offers four business services- from medical devices to nutritionals as well as diagnostics and generic pharmaceuticals.
Growth opportunity high
Abbott Laboratories (NYSE:ABT) typically has it earnings coming in from different regions of the world, given its world-wide footprint. The company has also offered a solid dividend yield and is set to grow on a short-term growth curve. The company is also expected to see fair price on the earnings front and is expected to see high growth potential. The dividend is also expected to be secure and will see return on the equity front as well. As far as the technical basis is concerned, there is quick momentum happening on the bullish conditions. The technical issues which the company will see are expected to see high returns on the equity as well. Moreover, the technical issues which see high bullish phase are also where the returns on equity are available. The near-term earnings are expected to grow and the potential breached.
Earnings report
Besides, the company has also reported earnings aligned at $0.58 per share. These will be in-line with the estimates which are $5.65 billion. The missed estimates are in the region of $70 million. Abbott Laboratories (NYSE:ABT) has also increased the share repurchase from 2014 to $2 billion and more.
However, the verdict of the court suit is awaited to see which way Abbott Laboratories (NYSE:ABT) stocks are headed over the next couple of weeks.
